Recent Updates
Recently added Catalysts
DNTH Positive Sentiment

Dianthus Therapeutics to Participate in Four Investor Conferences During November

Tuesday, November 4, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Dianthus Therapeutics, a clinical-stage biotech firm, announced its participation in four investor conferences in November. CEO Marino Garcia will engage in fireside chats and one-on-one meetings to discuss the company's innovative therapies aimed at treating severe autoimmune diseases. This initiative reflects the company's commitment to investor relations and transparency.
Price reaction · baseline $34.03 (2025-11-03 close) · hit pre-market · 1 other DNTH headline(s) in the window, move may be shared
day 0 close · peak
-2.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dianthus Therapeutics is actively engaging with investors.
  • Participation in multiple conferences indicates strong investor interest.
  • The company focuses on transformative therapies for severe autoimmune diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+165%
120-day peak, hindsight
Typical move
3.2%
average across 2 past catalysts
Cash runway
~54 mo
Minimal dilution risk
Lead asset
MGTA-456
Phase 2 · Inherited Metabolic Disorders (IMD)

Full Press Release Details

NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the company’s participation in four upcoming investor conferences.
Marino Garcia, CEO of Dianthus Therapeutics, will participate in fireside chats and host one-on-one investor meetings at the following conferences:
Webcasts of these presentations may be accessed under “News and Events” in theInvestorssection of the Dianthus Therapeuticswebsite.
About Dianthus TherapeuticsDianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visitwww.dianthustx.comand follow us onLinkedIn.

ContactJennifer Davis RuffDianthus Therapeuticsjdavisruff@dianthustx.com

Frequently Asked Questions

What is the purpose of Dianthus Therapeutics' conferences?

The conferences aim to engage investors and discuss the company's innovative therapies.

Who will represent Dianthus at the investor conferences?

CEO Marino Garcia will participate in fireside chats and one-on-one meetings.

Where can I access the webcasts of the presentations?

Webcasts will be available under 'News and Events' on the Dianthus website.

What is the focus of Dianthus Therapeutics?

Dianthus focuses on developing therapies for severe autoimmune diseases.

ShareAdd on Google
Tags: DNTH Viatris Investor Conferences Healthcare Dianthus Therapeutics investor conferences autoimmune diseases biotechnology
Last updated: Nov 4, 2025

Biotech snapshot

Cash runway
$887M liquidity · $16M/mo burn
~54 mo
Minimal dilution risk
Lead asset
MGTA-456Phase 2
Inherited Metabolic Disorders (IMD) →

Catalyst track record

+165%
best trade around DNTH's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DNTH.

See every catalyst's timing & PoA →